Literature DB >> 23403804

Acute and sustained effects of aerosolized vs. bolus surfactant therapy in premature lambs with respiratory distress syndrome.

Carmen Rey-Santano1, Victoria E Mielgo, Leire Andres, Estibaliz Ruiz-del-Yerro, Adolfo Valls-i-Soler, Xabier Murgia.   

Abstract

BACKGROUND: Surfactant (SF) instillation may produce acute deleterious effects on gas exchange and both systemic and cerebral hemodynamics. Our aim was to compare the effects of aerosolized SF (SF-aero) with those of bolus SF (SF-bolus) administration on gas exchange, lung mechanics, and cardiovascular function in premature lambs with respiratory distress syndrome (RDS).
METHODS: Fourteen preterm lambs (85% gestation) were randomly assigned to receive SF-aero or SF-bolus. Oxygenation index (OI), PaCO2, cardiovascular parameters, carotid blood flow (CBF), lung compliance (mean dynamic compliance), and tidal volume (VT) were measured every 30 min for 6 h. Biochemical and histological analyses were performed.
RESULTS: After delivery, lambs developed severe RDS (inspiratory fraction of oxygen: 1; pH < 7.15; PaCO2 > 80 mm Hg; PaO2 < 30 mm Hg, mean dynamic compliance < 0.08 ml/cm H2O/kg). By 60 min after treatment, both groups showed an improvement in OI, PaCO2, mean dynamic compliance, and VT that was maintained until the end of the experiment. PaCO2 and CBF increased significantly in the SF-bolus group during the first 15-30 min, without concomitant changes in cardiovascular parameters, whereas in the SF-aero group, PaCO2 and CBF decreased gradually. SF-aero induced less alveolar hemorrhage and inflammation.
CONCLUSION: SF-aero produced improvements in gas exchange and lung mechanics similar to those produced by bolus administration but with less lung injury and fewer cerebral hemodynamic changes.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23403804     DOI: 10.1038/pr.2013.24

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  11 in total

1.  Nebulization of Poractant alfa via a vibrating membrane nebulizer in spontaneously breathing preterm lambs with binasal continuous positive pressure ventilation.

Authors:  Matthias C Hütten; Elke Kuypers; Daan R Ophelders; Maria Nikiforou; Reint K Jellema; Hendrik J Niemarkt; Carola Fuchs; Markus Tservistas; Roberta Razetti; Federico Bianco; Boris W Kramer
Journal:  Pediatr Res       Date:  2015-08-31       Impact factor: 3.756

2.  Intratracheal atomized surfactant provides similar outcomes as bolus surfactant in preterm lambs with respiratory distress syndrome.

Authors:  Ilaria Milesi; David G Tingay; Emanuela Zannin; Federico Bianco; Paolo Tagliabue; Fabio Mosca; Anna Lavizzari; Maria Luisa Ventura; C Elroy Zonneveld; Elizabeth J Perkins; Don Black; Magdy Sourial; Raffaele L Dellacá
Journal:  Pediatr Res       Date:  2016-03-08       Impact factor: 3.756

3.  In vitro and in vivo characterization of poractant alfa supplemented with budesonide for safe and effective intratracheal administration.

Authors:  Francesca Ricci; Chiara Catozzi; Francesca Ravanetti; Xabier Murgia; Francesco D'Aló; Natalia Macchidani; Elisa Sgarbi; Valentina Di Lallo; Federica Saccani; Marisa Pertile; Antonio Cacchioli; Silvia Catinella; Gino Villetti; Maurizio Civelli; Francesco Amadei; Fabio Franco Stellari; Barbara Pioselli; Fabrizio Salomone
Journal:  Pediatr Res       Date:  2017-08-23       Impact factor: 3.756

Review 4.  Delivery and performance of surfactant replacement therapies to treat pulmonary disorders.

Authors:  Nashwa El-Gendy; Anubhav Kaviratna; Cory Berkland; Prajnaparamita Dhar
Journal:  Ther Deliv       Date:  2013-08

5.  Physiological, Biochemical, and Biophysical Characterization of the Lung-Lavaged Spontaneously-Breathing Rabbit as a Model for Respiratory Distress Syndrome.

Authors:  Francesca Ricci; Chiara Catozzi; Xabier Murgia; Brenda Rosa; Davide Amidani; Luca Lorenzini; Federico Bianco; Claudio Rivetti; Silvia Catinella; Gino Villetti; Maurizio Civelli; Barbara Pioselli; Carlo Dani; Fabrizio Salomone
Journal:  PLoS One       Date:  2017-01-06       Impact factor: 3.240

6.  In Vivo Evaluation of the Acute Pulmonary Response to Poractant Alfa and Bovactant Treatments in Lung-Lavaged Adult Rabbits and in Preterm Lambs with Respiratory Distress Syndrome.

Authors:  Francesca Ricci; Fabrizio Salomone; Elke Kuypers; Daan Ophelders; Maria Nikiforou; Monique Willems; Tobias Krieger; Xabier Murgia; Matthias Hütten; Boris W Kramer; Federico Bianco
Journal:  Front Pediatr       Date:  2017-08-31       Impact factor: 3.418

Review 7.  Carriers for the targeted delivery of aerosolized macromolecules for pulmonary pathologies.

Authors:  Nashwa Osman; Kan Kaneko; Valeria Carini; Imran Saleem
Journal:  Expert Opin Drug Deliv       Date:  2018-07-26       Impact factor: 6.648

8.  In vitro characterization and in vivo comparison of the pulmonary outcomes of Poractant alfa and Calsurf in ventilated preterm rabbits.

Authors:  Xiaojing Guo; Siwei Luo; Davide Amidani; Claudio Rivetti; Giuseppe Pieraccini; Barbara Pioselli; Silvia Catinella; Xabi Murgia; Fabrizio Salomone; Yaling Xu; Ying Dong; Bo Sun
Journal:  PLoS One       Date:  2020-03-13       Impact factor: 3.240

9.  Surfactant lung delivery with LISA and InSurE in adult rabbits with respiratory distress.

Authors:  Francesca Ricci; Ilia Bresesti; Paola Azzurra Maria LaVerde; Fabrizio Salomone; Costanza Casiraghi; Arianna Mersanne; Matteo Storti; Chiara Catozzi; Laura Tigli; Riccardo Zecchi; Pietro Franceschi; Xabier Murgia; Manuela Simonato; Paola Cogo; Virgilio Carnielli; Gianluca Lista
Journal:  Pediatr Res       Date:  2021-01-15       Impact factor: 3.756

10.  In vitro surfactant and perfluorocarbon aerosol deposition in a neonatal physical model of the upper conducting airways.

Authors:  Estibalitz Goikoetxea; Xabier Murgia; Pablo Serna-Grande; Adolf Valls-i-Soler; Carmen Rey-Santano; Alejandro Rivas; Raúl Antón; Francisco J Basterretxea; Lorena Miñambres; Estíbaliz Méndez; Alberto Lopez-Arraiza; Juan Luis Larrabe-Barrena; Miguel Angel Gomez-Solaetxe
Journal:  PLoS One       Date:  2014-09-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.